- contact us
Emergent BioSolutions Inc. at Jefferies Global Healthcare Conference (Live)
06/03/13 at 9:00 a.m. ET
Emergent BioSolutions 2013 Annual Shareholders Meeting (Replay)
05/23/13 at 9:00 a.m. ET
A copy of the company’s Form 10-K, including the company’s completed audited financial statements, for the year ended December 31, 2012, filed with the Securities and Exchange Commission, is available without charge, upon written request to Investor Relations, Emergent BioSolutions Inc., Suite 400, Rockville, MD 20850.
|Webcasts & Presentations|
|Receive Email Alerts|
|Sign up to receive Email alerts whenever Emergent BioSolutions Inc. posts new information to the site. Just enter your Email address and click Submit.|
|Safe Harbor Statement|
|The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including our expected revenue growth and net earnings for 2012, and any other statements containing the words “believe”, “expect”, “anticipate”, “plan”, “intend”, “estimate”, “may”, “will”, “would” and similar expressions, are forward-looking statements, although not all forward-looking statements contain these identifying words. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including our ability to perform under our contracts with the U.S. government for sales of BioThrax® (Anthrax Vaccine Adsorbed), including the timing of deliveries; our plans for future sales of BioThrax, including our ability to obtain new contracts or modifications to existing contracts with the U.S. government; ; our plans to pursue label expansions and improvements for BioThrax®; our ability to perform under our development contract with the U.S. government for PreviThrax™ (Recombinant Protective Antigen Anthrax Vaccine, Purified); our ability to perform under our contract with the U.S. government to develop and obtain regulatory approval for large-scale manufacturing of BioThrax in Building 55, our large-scale vaccine manufacturing facility in Lansing, Michigan; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance of our products and product candidates; the success of our ongoing and planned development programs, preclinical studies and clinical trials of our product candidates and post-approval clinical utility of our products; our ability to identify and acquire or in-license products and product candidates that satisfy our selection criteria; our ability to successfully integrate and develop the products or product candidates, programs, operations and personnel of any entities or businesses that we acquire; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our other product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property portfolio; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2012 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements contained in or directly accessible from documents on this website.|
|Quotes delayed at least 15 minutes. Market data provided by Interactive Data.|
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.